A case of Pseudomonas aeruginosa septicemia complicated by ecthyma gangrenosum is presented. The usefulness of monitoring aminoglycoside concentrations in the treatment of septicemia is stressed. The pathophysiology and treatment of ecthyma gangrenosum and the pharmacokinetics of tobramycin are reviewed.
Get full access to this article
View all access options for this article.
References
1.
LoeblECMarvinJASurvival with ecthyma gangrenosum, a previously fatal complication of burns. J Trauma1974; 14: 37–77.
ZaskeDESawchukRJIncreased dosage requirements of gentamicin in burn patients. J Trauma1976; 16: 824–8.
4.
ReedRLLarterWESeiberOTPeripheral nodular lesions in pseudomonas sepsis: the importance of incision and drainage. J Pediatr1976; 88: 977–9.
5.
ZaskeDEStrateRGIndividualized aminoglycoside therapy based on pharmacokinetic analysis (personal communication).
6.
BaxterCRMoncriefJAPragerMDA circulating MDF in burn shock. In: MatterPBarclayTLKonicfovaZ.Research in burns transactions of Third International Conference in Research in Burns, Prague, September 20–25, 1970. Bern, Switzerland: Hans Huber Verlag, 1971: 491–503.
7.
ArtzCP.Burns updated. J Trauma1976; 16: 3–15.
8.
HitschmanRKreibickK.Zur pathogenese des bacillus pyocyaneus und zur zefiologic des ekthyma gran grae nosum. Wien Klin Wochenschr1897; 10: 1093.
9.
BarkerLF.The clinical symptoms, bacteriologic findings and postmortem appearances in cases of infection of human beings with the Bacillus pyocyaneus. JAMA1897; 29: 213.
10.
FrankelE.Weitere untersuchungen uber die menschen-pathogenitat des Bacillus pyocyaneus. Z Hyg Infektionshr1917; 84: 369.
11.
MarkleyKGurmendiGFatal pseudomonas septicemia in burned patients. Ann Surg1957; 145: 175.
12.
AppelGNeuHC.Gentamicin in 1978. Ann Intern Med1978; 89: 528–38.
13.
WeberRW.Pseudomonas septicemia ecthyma gangrenosum successfully treated with gentamicin and carbenicillin. J Kans Med Soc1971; 72: 462–4.
14.
TeplitzC.Pathogenesis of pseudomonas vasculitis and septic lesions. Arch Pathol1965; 80: 297–307.
15.
HallJHCallawayJLPseudomonas aeruginosa in dermatology. Arch Dermatol1968; 97: 312–24.
16.
BodeyGPWhitecarJPCarbenicillin therapy for pseudomonas infections. JAMA1971; 218: 62–6.
17.
PriorRFassR.Comparison of ticarcillin and carbenicillin activity against random and select populations of Pseudomonas aeruginosa. Antimicrob Agents Chemother1977; 13: 184–7.
18.
ParryMNeuH.A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli. Am J Med1978; 64: 961–6.
19.
ValdiviesoMHorikoshiNTherapeutic trials with tobramycin. Am J Med Sci1974; 268: 149–56.
20.
KlugeRMStandifordHCTatemBThe carbenicillin-gentamicin combination against Pseudomonas aeruginosa: correlation of effect with gentamicin sensitivities. Ann Intern Med1974; 81: 584–7.
21.
KlasterskyJMeunier-CarpentierFSignificance of antimicrobial synergism for the outcome of gram-negative sepsis. Am J Med Sci1977; 273: 157–67.
22.
MoelleringRCJrWeinbergAN.Studies on antibiotic synergism against enterococci. II: Effect of various antibiotics on the uptake of C14-labelled streptomycin by enterococci. J Clin Invest1971; 50: 2580–4.
23.
KlasterskyJHenriAVandenborreL.Antimicrobial activity of tobramycin and gentamicin used in combination with cephalothin and carbenicillin. Am J Med Sci1973; 266: 13–21.
24.
KlasterskyJCappelRDaneauD.Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother1972; 2: 470–5.
25.
SawchukRJZaskeDE.Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm1975; 4: 183–95.
26.
ZaskeDEStrateRGIncreased patient survival and decreased toxicity with individualized aminoglycoside therapy (personal communication).
27.
BarzaMScheifeRT.Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 4: aminoglycosides. Am J Hosp Pharm1977; 34: 723–37.
DahlgrenJAndersonEHewittW.Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother1975; 8: 58–62.
30.
BarzaMLauermannM.Why monitor serum levels of gentamicin? Clin Pharmacokinet1978; 3: 202–15.
31.
SchentagJJuskoWTissue persistence of gentamicin in man. JAMA1977; 238: 327–9.
32.
SchentagJJuskoW.Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther1977; 22: 364–70.
33.
SchentagJLasezkayGAccumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother1978; 13: 649–56.
34.
MahonW.Assessment of aminoglycoside toxicity. A symposium sponsored by Eli Lilly, September 24, 1977: 14–19.
35.
LoiratPRohanJIncreased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med1978; 299: 915–9.
36.
SarubbiFHullJH.Amikacin serum concentrations: prediction of levels and dosage guidelines. Ann Intern Med1978; 89 (Part I): 612–8.
37.
HullJHSarubbiF.Gentamicin serum concentrations: pharmacokinetics predictions. Ann Intern Med1976; 85: 183–9.
38.
ReymannMTBradacJACorrelation of gentamicin and tobramycin with concentrations in serum during therapy. Current chemotherapy. Proceedings of the 19th International Congress of Chemotherapy.
39.
StevenPYoungLHewittW.Radioimmunoassay, acetylating radioenzymatic assay, and microbioassay of gentamicin: a comparative study. J Lab Clin Med1975; 86: 349–59.
40.
WintersRLitwackKHewittW.Relation between dose and level of gentamicin in blood. J Infect Dis1971; 124 (suppl): 590–5.
41.
GiamarellouHSimelisVAssay of aminoglycoside antibiotics in clinical specimens. J Infect Dis1975; 132: 399–405.
42.
SawchukRJZaskeDEKinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther1977; 21: 362–9.
43.
Linear Regression Program STI-08. Texas Instru., Inc.
